From: www.ecancer.tv on Mon, Jan 31 2011 2:42 PM

Dr Luca Toschi speaks about molecular biomarkers and acquired resistance to new target agents. A number of speakers at ESMO 2010 have stressed the important of collecting tissue samples before treatment in order to identify any potential biomarkers and this is likely to become more important as t...

From: www.ecancer.tv on Mon, Jan 31 2011 2:42 PM

Prof. Giorgio Parmiani speaks about the potential benefit of new anti-BRAF drugs and discusses patient response and side effects seen in patients treated with ipilimumab. Prof. Parmiani explains how ipilimumab side effects are managed, talks about the need to educate clinicians about this new cl...

From: www.ecancer.tv on Mon, Jan 31 2011 2:42 PM

Prof Fausto Roila speaks about two studies presented at ESMO 2010. The first of these involved 'Balloon Kyphoplasty', a new minimally invasive procedure for painful vertebrae fractures. This procedure reduces pain and disability by inserting a small orthopaedic balloon into the fractur...

From: www.ecancer.tv on Thu, Jan 27 2011 10:11 AM

Prof Matti Aapro (University of Geneva) Prof Joachim Fandrey (Essen University, Germany) Prof Dirk Schrijvers (Middelheim Hospital, Antwerp) and Prof Anders Österborg (Karolinska Institutet, Stockholm) discuss the best way to manage anaemia in cancer patients, at the Anaemia Management Update me...

From: www.ecancer.tv on Tue, Jan 25 2011 2:01 PM

Prof. Berksoy Sahin speaks in Turkish about the challenges faced in treating soft tissue sarcoma in Turkey.

From: www.ecancer.tv on Tue, Jan 25 2011 2:01 PM

Prof Joan Albanell Mestres speaks in Spanish about his research into the clinical utility of Oncotype DX testing in breast cancer patients. This test was used on a group of oestrogen receptor-positive node-negative breast cancer patients to decide if their adjuvant therapy should be hormone thera...

From: www.ecancer.tv on Tue, Jan 25 2011 2:01 PM

Dr Alexander Fedenko speaks in Russian about the work of the East European Sarcoma Group and the challenges faced in treating soft tissue sarcoma in Russia.

From: www.ecancer.tv on Mon, Jan 24 2011 5:50 AM

Prof Joan Albanell Mestres speaks about his research into the clinical utility of Oncotype DX testing in breast cancer patients. This test was used on a group of oestrogen receptor-positive node-negative breast cancer patients to decide if their adjuvant therapy should be hormone therapy alone or...

From: www.ecancer.tv on Mon, Jan 24 2011 5:50 AM

Prof Christian Marth discusses whether clinicians should continue to follow-up ovarian cancer patients using the CA-125 tumour marker. A recent study has shown that early treatment in response to a rise in this tumour marker does not increase patient survival; however the patients in this study d...

From: www.ecancer.tv on Thu, Jan 20 2011 8:39 AM

The Tenovus Sing For Life Choir perform at the National Cancer Resarch Institute Conference at the BT Convention Centre, Liverpool, 7.11.10. A truly remarkable choir made up of people who have been affected by cancer; the Sing for Life Choir was established in January, initially as a research pr...

From: www.ecancer.tv on Wed, Jan 19 2011 7:50 AM

Dr Perez talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about a debate she took part in on the use of Avastin (Bevacizumab) for metastatic breast cancer and also her recent analysis of HER2 breast cancer tests, revealing issues with reliability. Results for testing breast tum...

From: www.ecancer.tv on Wed, Jan 19 2011 7:50 AM

Prof Workman talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium, explaining what molecular chaperones are and their role in causing cancer. He discusses the first generation of Hsp90 (Heat Shock Protein 90) inhibitors and the ICR’s creation of a 2nd generation of Hsp90 inhibitors...

From: www.ecancer.tv on Wed, Jan 19 2011 7:50 AM

Dr Faratian talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about using 'systems biology' to improve trial design and treatment. In this case systems biology is a framework for analyzing a particular biological process, using maths, or tumour interactions etc. Dr Far...

From: www.ecancer.tv on Wed, Jan 19 2011 7:50 AM

Prof Robertson talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about fulvestrant (500mg dose) in comparison to the aromatase inhibitor, anastrozole, when used as a first-line treatment for hormone receptor positive breast cancer. Follow-up data from the FIRST (FASLODEX fIRst l...

From: www.ecancer.tv on Wed, Jan 19 2011 7:50 AM

Prof Kantel talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about his work with circulating tumour cells, and the potential for clinical application. A simple blood test can give instant feedback as to what therapy is required and the success of therapy given.

From: www.ecancer.tv on Wed, Jan 19 2011 7:50 AM

Nancy Lin discusses the session she chaired at the 2010 San Antonio Breast Cancer Symposium on metastases in breast cancer, and specifically her talk on trying to tackle cancer that has spread to the central nervous system by chemotherapy and targeted therapies. Also taking into account the type...

From: www.ecancer.tv on Wed, Jan 19 2011 7:50 AM

Prof Garth Powis talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about how causing stress to tumours by increasing hypoxia to reduce tumour resistance to chemotherapy and radiotherapy. Increase in glycolytic enzymes stimulates hypoxia (decreased blood flow to tumour). Increased...

From: www.ecancer.tv on Wed, Jan 19 2011 7:50 AM

Professor Michael Gnant talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium. Zometa, an osteoporosis drug from Novartis, failed to improve disease free survival of early breast cancer patients in a substantial clinical trial. The AZURE trial included 3360 patients from 174 centres...

From: www.ecancer.tv on Wed, Jan 19 2011 7:50 AM

Prof Charles Perou talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about next generation sequencing and whole genome sequencing and their application to breast cancer. He discusses using sequencing technology to study gene expression, and how that compares and contrasts with m...

From: www.ecancer.tv on Tue, Jan 18 2011 6:23 AM

For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010. "The average life e...